HOSPITAL support services-based Faber Group Bhd is now seen to be in a healthier position with the completion of its restructuring exercise last year, which saw its liabilities reduced to RM250mil from RM1.2bil previously.
AmResearch, in recommending a “buy” on Faber shares, said the company's stock valuation was attractive with its strong balance sheet and healthy prospects.
